Cargando…
Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy
Most patients who develop rectal cancer present with locoregionally advanced (T3 or node-positive) disease. The standard management of locoregionally advanced rectal cancer is neoadjuvant concurrent chemoradiotherapy (nCRT), followed by radical resection (low-anterior resection or abdominoperineal r...
Autores principales: | Solanki, Abhishek A, Chang, Daniel T, Liauw, Stanley L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747849/ https://www.ncbi.nlm.nih.gov/pubmed/23983475 http://dx.doi.org/10.2147/OTT.S34869 |
Ejemplares similares
-
Total mesorectal excision for the treatment of rectal cancer
por: Zedan, Ali, et al.
Publicado: (2015) -
Robotic Total Mesorectal Excision for Rectal Cancer: Current Evidences and Future Perspectives
por: Jang, Je-Ho, et al.
Publicado: (2020) -
Robotic total mesorectal excision for the treatment of rectal cancer
por: Baik, Seung Hyuk, et al.
Publicado: (2007) -
Update on Robotic Total Mesorectal Excision for Rectal Cancer
por: Giuratrabocchetta, Simona, et al.
Publicado: (2021) -
Local Excision ± Chemoradiotherapy vs. Total Mesorectal Excision for Early Rectal Cancer: Case-Matched Analysis of Long-Term Results
por: Pacevicius, Julius, et al.
Publicado: (2021)